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Abstract
Aim: To provide a description of patients receiving alcohol treatment in eight different European
countries, including the level of comorbidities and functional limitations.
Methods: Drinking behaviours, DSM-IV alcohol use disorder (AUD), mental and somatic comorbid-
ities, disability and health services utilization of 1767 patients from various specialized treatment set-
tings were assessed as representative for regions of eight European countries. Severity of alcohol
dependence (AD) in terms of drinking level was compared with a large representative US sample.
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Results: Patients in specialized care for AUDs showed high levels of consumption [average level of
daily ethanol intake: 141.1 g, standard deviation (SD): 116.0 g], comorbidity [e.g. liver problems:
19.6%, 95% conﬁdence interval (CI): 17.5–21.6%; depression: 43.2%, 95% CI: 40.7–45.8%; anxiety:
50.3%, 95% CI: 47.8–52.9%], disability and health services utilization (average number of nights
spent in hospital(s) during the last 6 months: 8.8, SD: 19.5 nights). Severity of AD was similar to
the US sample, but European men consumed on average more alcohol daily.
Conclusions: High levels of consumption, somatic and mental comorbidities, disability and func-
tional losses were found in this representative treatment sample, indicating that treatment was in-
itiated only at severe stages of AUDs. Earlier initiation of treatment could help avoid some of the
health and social burden.
INTRODUCTION
Alcohol use disorders (AUDs) in general and alcohol dependence (AD)
in particular are highly prevalent and disabling conditions in the Euro-
pean Union (EU). AUD here is deﬁned as fulﬁlling the diagnostic
criteria of AD and/or alcohol abuse, as deﬁned in the DSM-IV.
Regarding prevalence, the most recent overview (Rehm et al.,
2015b) found a prevalence of AD 3.4% for both sexes combined in
2010 for people aged 18–64 (1.7% among women and 5.2%
among men), which translates into an estimated 11 million people
with AD in the EU. For all AUD, the estimate was about 23 million
people affected (Rehm et al., 2015b). It should be noted that these
numbers are based on general population surveys with standardized
instruments which do not include people with AD or AUD among
the homeless (Fazel et al., 2008), the prison population (Fazel et al.,
2006) or in mental institutions (Shield and Rehm, 2012), meaning
that the numbers are likely underestimates. In addition, a large
study in primary care in six EU countries showed that standardized in-
strumentsmay underestimate the true prevalence of AUD, especially in
age groups 40 and above (Rehm et al., 2015a).
With respect to disability and burden of disease, recent studies
have revealed not only a high degree of comorbidity and disability
(Samokhvalov et al., 2010; Rehm et al. 2014b, 2015a), but also a sur-
prisingly high rate of fatalities (for meta-analyses, see Roerecke and
Rehm, 2013, 2014).
Despite this burden, treatment rates for AD or AUDs have been
low, especially rates in specialized treatment. Alonso and co-workers
found a treatment rate of 8.3% among peoplewith AUD in the general
population in six countries in western Europe, who participated in the
WorldMental Health Survey between January 2001 and August 2003
(Alonso et al., 2004); and Rehm and colleagues, with different meth-
ods, 10 years later, estimated about the same proportion for the EU as
a whole (Rehm et al. 2012, 2013c). The high treatment gap was also
corroborated by Drummond et al. (2011).
Whilewe can estimate treatment rates based on aggregate statistics,
not much is known about the characteristics of people who seek treat-
ment for AUD or AD in the EU. There are two main sources of infor-
mation on patients in AUD treatment: (a) ofﬁcial statistics on
patients treated for substance use disorders (including alcohol) in
different institutions (e.g. Agència de salut pública de Barcelona,
2012; Italian Ministry of Health, 2013), and (b) single studies in se-
lected in- or outpatient facilities, not representative for an entire re-
gion or country (e.g. Röske et al., 2004; Picci et al., 2012). However
neither source could give detailed characteristics of a representative
sample of treated AUD patients for larger regions or countries in
Europe for characteristics such as, but not limited to, comorbidity
or problem severity indicators.
There have been some indications that AD in specialized health
care (SC) is more severe in Europe compared with North America
(e.g. in terms of more DSM-IV symptoms experienced; more standard
drinks per occasion and more heavy drinking days in the German ver-
sion of the Combine study compared with the US original study;
Mann et al., 2013), but we do not know how representative the
study populations showing differences had been (Bottlender et al.,
2006), and whether other factors such as age are the main determi-
nants on such differences. The latter seems plausible (albeit not for
the Mann et al., 2013, study), as prevalence of AD in adolescence
and early adulthood seems to be considerably higher in North Amer-
ica (especially the US, cf. Grant et al., 2004; Caetano and Babor,
2006;) compared with Europe (Rehm et al., 2005), at least in general
population samples.
The objective of this contribution was to ﬁll the above-described
gap in the literature, and to describe representative samples from spe-
cialized treatment in European regions or countries. More speciﬁcally,
we wanted to characterize SC patients with respect to:
• sociodemographics;
• their alcohol consumption, symptoms of DSM-IV AUD and
severity of AUD;
• mental and somatic comorbidity, and associated disability;
• health service utilization.
In addition, we wanted to compare patients from different treatment
settings (inpatients vs. outpatients vs. rest) and examine whether our
treatment sample differed from a representative sample in the US with
respect to average daily drinking.
MATERIALS AND METHODS
This assessment of AUDs in SC facilities was complementary to the
Alcohol Dependence in Primary Care (APC) study (Manthey et al.,
2014; Rehm et al., 2015a), which assessed prevalence and detection
of AUDs in primary care settings. While the ﬁrst part was restricted
to regions in six European countries, the second part extended
its scope to regions in eight European countries, namely Austria
(Carinthia), France (sampling was based on whole country), Germany
(Saxony & Berlin-Brandenburg), Hungary (whole country), Italy
(Friuli-Venezia Giulia & Tuscany), Latvia (whole country), Poland
(Pomorskie, Warminsko-Mazurskie, Dolnoslaskie, Podlaskie,
Podkarpackie & Malopolskie) and Spain (Catalonia). In total, 1767
patients from 45 SC facilities and various self-help groups were re-
cruited for this study. Monetary compensation of goods or vouchers
was offered to the clinics and/or professionals participating in the
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study in Austria, France, Latvia and Poland. Interviews were con-
ducted between January 2013 and March 2014.
Sampling of AUD treatment providers in eight
European countries
Treatment provision for AUD in Europe differs greatly, with varia-
tions being understudied (European Commission, 2004; Drummond
et al., 2011; Rehm et al., 2013b). However, we tried to account for
and represent country- or region-speciﬁc characteristics and included
patients receiving various types of treatments for their alcohol pro-
blems. Broadly, institutionalized and non-institutionalized treatment
options have been identiﬁed. A brief description of sampled treatment
facility types is available in Supplementary Appendix 1.
The type of treatment facility as sampled by each country is sum-
marized in Table 1. Most commonly, patients included in this study
were admitted as inpatients (55.9%), followed by those in outpatient
treatment (34.0%). Some patients were also treated by a registered
psychiatrist (4.2%) or were recruited from other non-institutionalized
treatment providers (5.9%), mostly self-help groups. However,
marked differences between countries could be observed: in Austria,
all patients received inpatient treatment, whereas all Spanish patients
were recruited from outpatient treatment facilities (reﬂecting the or-
ganization of the Catalonian treatment system for AUD; see Supple-
mentary Appendix 1). Regarding non-institutionalized treatment,
patients in treatment with a psychiatrist were recruited foremost in
Hungary (28.4% of Hungarian patients) and self-help groups were
most highly represented in Italy (31.9% of Italian patients).
Patient interview
In most countries, all patients aged 18–64 years receiving current in-
terventions for their alcohol problems on a given day were asked to be
interviewed. Interviewees in Friuli-Venezia Giulia (Italy) were con-
tacted if they were present on a given day, and were called if not pre-
sent but registered on a SC list. In Poland, admission to the SC facility
implied participation in this study. Hence, all newly admitted patients
could be recruited there with interviews being conducted within
1–2 weeks after admission.
More than 9 out of 10 patients were interviewed in the respective
SC facility. All interviews were conducted by trained interviewers
across all countries. Computer-assisted personal interviews were
used in Austria, Germany, Latvia and Spain. In the remaining coun-
tries, paper and pencil were used to document the interview.
The basic structure and content of the patient interview was
similar to the interview conducted in the APC study (see Manthey
et al., 2014) and began with obtaining informed consent and
comprised a socio-demographic part, the World Health Organization
Disability Assessment Schedule 2.0 (WHODAS 2.0; Üstün et al.,
2010), the Kessler Psychological Distress Scale (K10) to identify severe
mental problems (Kessler et al., 2002), the Composite International
Diagnostic Interview—CIDI (Robins et al., 1988) and the UK alcohol
treatment trial health service utilization questionnaire (UKATT
Research Team, 2005). We also assessed self-reported height,
weight and select somatic (hypertension, liver) and mental co-
morbidities. Monetary compensation for interviewees was offered
in most countries: Austria (15€), Germany (20€), Hungary (2€ gift
coupon), Latvia (3€) and Spain (20€).
Comparison with US sample
We compared our sample with the treated subsample of the large
(N = 43,093) NESARC study, representative for the US for the years
2001/2002, with respect to the level of consumption among current
drinkers (in g/day with a cap of 500 g/day and excluding current
abstainers as deﬁned by less than 10 g/day) via linear regression for
men and women separately, controlling number of AD criteria. Add-
itionally we analysed differences in the number of AD criteria between
samples via a quasi-poisson regression for men andwomen separately.
All regression models took into account the complex sampling design
of the NESARC survey and were performed using R version 3.1.1
(R Development Core Team, 2014) and the R survey statistical pack-
age (Lumley, 2004). The NESARC sample has been described in detail
elsewhere (Grant et al., 2003).
Statistical methodology
Missing values were imputed for scales if only single items were miss-
ing. Other missing cases were not included in the analyses. All analyses
other than the comparison with NESARC were conducted using Stata
12 (Stata Corporation, 2011). In order to test for country differences
on key drinking variables we carried out ANOVAs (for average daily
intake of ethanol) and logistic regressions (for percentage of patients
with weekly binge drinking or chronic heavy drinking habits), both
adjusted by age and sex. If the overall model was signiﬁcant, each
country was compared against the remaining countries using the
same procedure. In order to account for multiple testing, the signiﬁ-
cance level was Bonferroni-adjusted.
RESULTS
Response and refusals
Table 2 reports the countries and regions for which the selected SC fa-
cilities are representative. Most treatment centres were willing to take
Table 1. Type of treatment facility by country
Country Inpatient (N = 988) Outpatient (N = 600) Psychiatrist (N = 75) Other (N = 104) Such as
Austria (N = 33) % (CI) 100 (100.0–100.0) 0 (0.0–0.0) 0 (0.0–0.0) 0 (0.0–0.0) NA
France (N = 284) % (CI) 73.2 (68.1–78.4) 26.8 (21.6–31.9) 0 (0.0–0.0) 0 (0.0–0.0) NA
Germany (N = 232) % (CI) 81.9 (76.9–86.9) 12.1 (7.9–16.3) 0.4 (0.0–1.3) 5.6 (2.6–8.6) Counselling, self-help groups
Hungary (N = 254) % (CI) 27.6 (22.0–33.1) 42.5 (36.4–48.6) 28.7 (23.2–34.3) 1.2 (0.0–2.5) Family physician
Italy (N = 276) % (CI) 13.8 (9.7–17.8) 54.0 (48.1–59.9) 0.4 (0.0–1.1) 31.9 (26.4–37.4) AA & CAT clubs
Latvia (N = 250) % (CI) 64.0 (58.0–70.0) 36.0 (30.0–42.0) 0 (0.0–0.0) 0 (0.0–0.0) NA
Poland (N = 289) % (CI) 100 (100.0–100.0) 0 (0.0–0.0) 0 (0.0–0.0) 0 (0.0–0.0) NA
Spain (N = 149) % (CI) 0 (0.0–0.0) 100 (100.0–100.0) 0 (0.0–0.0) 0 (0.0–0.0) NA
Total (N = 1,767) % (CI) 55.9 (53.6–58.2) 34.0 (31.7–36.2) 4.2 (3.3–5.2) 5.9 (4.8–7.0) See above
CI = 95% CI based on standard error. AA = Alcoholics Anonymous. CAT =Club of Alcoholics in treatment.
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part in our study (average response rate on institutional level: 62.5%),
with refusal rates being 0% in Austria, Latvia, Poland and Spain; and
around 15% in Hungary and Italy. Higher refusals were encountered
in France (60%) and Germany (75%). Patient non-response rates ran-
ged from 0% in Poland to 30.3% in Germany (average response rate
on individual level: 82.73%). The sample of treatment providers is
thought to be representative for a total general population of over
110 million people (for details see Table 2).
Socio-demographic characteristics
About 72.4% [95% conﬁdence interval (CI): 70.3–74.4%] of all pa-
tients in specialized care were men (see Table 3). The average age was
46.3 years (standard deviation—SD: 10.1 years). A considerable por-
tion of patients was from lower socio-economic strata (44.3%; 95%
CI: 41.9–46.6%), and more than one-third of the patients were un-
employed (36.0%; 95% CI: 33.7–38.2%), considerably more than in
the adult general population in the EU which is slightly above 10%
(http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&language=
en&pcode=teilm020).
Alcohol consumption and criteria of AD
With respect to alcohol-related variables, there were some patients
who did not consume alcohol or had (compared with the average pa-
tient) very low alcohol consumption during the past year before the
interview. This surprising result was due to the deﬁnition of treatment
system in the various countries, which for instance included people in
AA self-help groups, requiring abstention. Of those drinking, as de-
ﬁned by a consumption of 10 g or more per day, the level of drinking
was very high: 58.0% of male patients (95% CI: 55.0–60.9%) and
41.6% of female drinkers (95% CI: 36.5–46.6%) had an average
daily volume of alcohol consumption of 100 g pure alcohol or higher,
with 152.5 g (SD: 122.9 g) among men and 108.2 g (SD: 85.0 g)
among women as average daily consumption, and 46.6% (95% CI:
43.6–49.6%) of men and 28.2% (95% CI: 23.6–32.7%) of women
had at least one binge drinking occasion consuming 200 g or more
per week.
At least one DSM-IVAD or abuse criterion was present in 9 out
of 10 of the patients (see Table 4). The average number of DSM-IV
AUD symptoms present was 5.4 (SD: 3.3 symptoms), with toler-
ance and role failures having the highest prevalence, being present
in two-thirds or three-fourths of the patients, respectively (see
Table 4).
Variability of key alcohol consumption measures
by study site and treatment setting
Differences in daily amount of alcohol used by drinking patients in the
12 months before treatment were observed between study sites (see
Table 5). In Germany (223.5 g; SD: 133.7 g), patients drunk more
than the overall average while in Latvia (96.9 g; SD: 97.9 g) and Pol-
and (91.0 g; SD: 83.2 g), the mean daily consumption was less than
average. The same pattern of differences could be observed regarding
chronic heavy drinking, i.e. using at least 100 g pure alcohol daily. Pa-
tients in Germany reported weekly binge drinking occasions more fre-
quently (67.3%; 95% CI: 61.1–73.4%), i.e. more than 200 g ethanol,
than average. Only Polish patients were found to experience less binge
drinking occasions (25.2%; 95%CI: 19.5–30.9%) comparedwith the
group mean. No differences in alcohol measures were found across
type of treatment setting after Bonferroni adjustments (see Supplemen-
tary Appendix 2).
Comorbidity and disability
The prevalence of self-reported somatic and mental comorbidities was
high. 73.7% (95% CI: 71.5–76.0%) indicated at least one occurrence
of hypertension, liver cirrhosis, depression or anxiety disorders,
34.8% (95% CI: 32.3–37.2%) had at least one somatic co-morbid
condition and 61.5% (95% CI: 59.0–64.0%) at least one mental. In
terms of standardized assessment, more than one-third of all patients
had serious mental distress, proportionally more females (43.0%;
95% CI: 38.6–47.4%) than male patients (33.3%; 95% CI: 30.7–
35.9%).Most somatic andmental comorbidity measures were equally
distributed across different types of treatment setting (inpatient vs.
outpatient vs. remaining settings, see Supplementary Appendix 3
and 4), except for the K10 mental distress measure which was found
to be higher in inpatients compared with outpatients (P = 0.0004; post
hoc test) and all remaining settings (P < 0.0001; post hoc test).
Table 2. Selected regions and countries, population size, number and refusal rates of specialized care facilities and number of patients
recruited
Country Represented region Population
size
Number of facilities
included
Refusal rate of
contacted facilities
Number of patients
included
Refusal rate of
contacted patients
Austria Carinthia 556,845 1 0% 33 17.0%
France Entire country 63,070,344 6 60% 284 20.0%
Germany Saxony &
Berlin-Brandenburg
9,847,937 5 75.0% 232 30.3%
Hungary Entire country 9,957,731 7 12.5% 254 10.6%
Italy Friuli-Venezia Giulia 1,221,860 5 16.7% 129 Not available
Tuscany 3,692,202 5 16.7% 147 19.3%
Latvia Entire country 2,023,825 7 0% 250 Not available
Poland Pomorskie 2,295,811 1 0% 46 0%
Warminsko-Mazurskie 1,446,915 1 0% 48 0%
Dolnoslaskie 2,909,997 1 0% 48 0%
Podlaskie 1,194,965 1 0% 48 0%
Podkarpackie 2,129,951 1 0% 49 0%
Malopolskie 3,360,581 1 0% 50 0%
Spain Catalonia 7,553,650 3 0% 149 25.1%
Total 111,262,614 45 37.5% 1,767 17.3%
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Disability and health services utilization were high as well: on average,
4 days in the last 4 weeks before treatment, patients could not carry
out their work or usual activities because of their health (see Table 3).
Measured with the WHODAS 2.0, a standardized scale, there was a
high level of disability approximately corresponding to the 80th per-
centile in the general population of the norming samples (Üstün
et al., 2010). Finally, health service utilization was high: in the last
6 months and excluding the current stay in specialized care, 57.5%
(95% CI: 55.2–59.8%) of the patients were admitted at least once to
a hospital. Those admitted to a hospital spent on average 14.1 nights
(SD: 19.8 nights) as inpatient or in accident and emergency depart-
ments. Across all patients, the average number of nights spent in any
service, also including specialized services for alcohol treatment,
added up to 8.8 nights (SD: 19.5 nights). Further, 67.8% (95%
CI: 65.6–70.0%) received some kind of service from their GP.
Comparison with US
The European treatment sample was compared with the US sam-
ple with respect to average drinking. While men showed higher
drinking levels with on average 23.9 g more alcohol being con-
sumed per day (95% CI: 1.1–46.7 g/day), there was no signiﬁcant
difference for women (with a tendency of European patients
drinking less). When age was added to the regression equation,
it did not signiﬁcantly contribute to explaining average level of
drinking. Furthermore the average numbers of criteria for AD in
the European sample and US sample were not statistically signiﬁ-
cantly different.
DISCUSSION
Overall, patients from various specialized treatment facilities in
eight European countries were interviewed with the following
main characteristics:
• patients were predominantly menwhich is no surprise, given the fact
that in all countries in Europe (World Health Organization, 2014)
there are more alcohol consumers among men than among women,
men have higher average levels of consumption, riskier drinking pat-
terns and considerably more alcohol-attributable disease burden in
general (Shield et al., 2012);
• a high prevalence of lower socio-economic classes and unemploy-
ment, consistent with the fact that lower socio-economic status is
associated with more negative consequences for the same amount
of drinking compared with higher status (Mäkelä and Paljärvi,
2008; Probst et al., 2014);
• high average consumption of alcohol, and extensive binge drinking
episodes, which are much higher than found in people with AD or
AUD in general population surveys even if controlled for number
of diagnostic criteria [e.g. NESARC in the US (Rehm et al., 2014a);
or in Germany (Rehm et al., 2014c)];
• high comorbidity, both somatic and psychiatric, with associated
high level of disability and health services utilization (Holder,
1998; Samokhvalov et al., 2010).
• Sampling from different treatment settings resulted in patients,
who reported similar levels of consumption and comorbidity,
except for severe mental distress which was found to be highest
in inpatients.
Table 3. Patient characteristics and key health and alcohol variables by sex
Male (N = 1,277) Female (N = 488) All (N = 1,767)
12-months AU prevalencea % (CI) 95.0 (93.8–96.2) 91.7 (89.2–94.2) 94.1 (93.0–95.2)
Age mean (SD) 46.1 (10.0) 46.7 (10.3) 46.3 (10.1)
SES—self classiﬁed % (CI)
Above average 5.5 (4.2–6.8) 5.1 (3.2–7.1) 5.4 (4.3–6.5)
Average 48.7 (46.0–51.5) 54.5 (50.1–59.0) 50.3 (48.0–52.7)
Below average 45.8 (43.0–48.5) 40.3 (36.0–44.7) 44.3 (41.9–46.6)
Unemployed for health or other reason % (CI) 36.8 (34.2–39.5) 33.6 (29.4–37.8) 36.0 (33.7–38.2)
Smoking % (CI) 73.8 (71.4–76.3) 67.6 (63.4–71.7) 72.0 (70.0–74.2)
BMIb mean (SD) 25.5 (4.2) 24.3 (5.0) 25.2 (4.5)
Hypertensionb % (CI) 21.9 (19.3–24.4) 18.6 (14.8–22.4) 20.9 (18.9–23.0)
Liver problemsb % (CI) 21.1 (18.6–23.6) 15.6 (12.1–19.2) 19.6 (17.5–21.6)
Depressionb % (CI) 38.8 (35.8–41.7) 54.7 (49.8–59.5) 43.2 (40.7–45.8)
Anxietyb % (CI) 46.9 (43.8–49.9) 59.3 (54.5–64.1) 50.3 (47.8–52.9)
K10
Above cut-off for serious mental distress % (CI) 33.3 (30.7–35.9) 43.0 (38.6–47.4) 36.0 (33.8–38.3)
Total score mean (SD) 15.8 (9.8) 18.1 (9.9) 16.4 (9.9)
WHODAS 2.0 mean (SD)
Total score 17.3 (18.3) 19.7 (20.0) 18.0 (18.8)
Number of days of inability to carry out usual activities or work
due to health condition
3.9 (7.5) 4.2 (7.8) 4.0 (7.6)
Amount of ethanol used daily (in gram) by drinkersa mean (SD) 152.5 (122.9) 108.2 (85.0) 141.1 (116.0)
Chronic heavy drinkinga % (CI) at least 100 g ethanol daily 58.0 (55.0–60.9) 41.6 (36.5–46.6) 53.7 (51.2–56.3)
Binge drinking a % (CI) at least one episode of 200 g ethanol
consumption weekly
46.6 (43.6–49.6) 28.2 (23.6–32.7) 41.9 (39.3–44.4)
CI = 95% CI based on standard error. SD = standard deviation. SES = socio-economic status. BMI = Body Mass Index. K10 = Kessler Psychological Distress Scale;
cut-off for severe mental distress was 21 points in a total score range from 0 to 40. WHODAS 2.0 =World Health Organization Disability Assessment Schedule 2—
total score range: 0–100.
aAnalyses were computed on patients reporting alcohol use of at least 10 g ethanol daily during the past 12 months, excluding 285 patients.
bNot assessed in Poland.
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The results of our study indicate a level of morbidity and severe loss of
functionality, which explains why people after treatment have a much
higher risk for mortality compared with people with AUD from the
general population (Roerecke and Rehm, 2013). They are also consist-
ent with the fact that heavy drinking is the underlying reason for the
high level of comorbidity and disability [see also (Rehm et al., 2013a,
2014a)], and if these drinking levels are not reduced during treatment,
they will lead to higher level of mortality as well (Roerecke et al., 2013).
As this is the ﬁrst large representative study on specialized care for AUD
in several European countries, the average level of the drinking and co-
morbidity is surprising; this is underlined by the fact that daily drinking
levels in men were higher than in the US (see above).
Table 5. Variability of key alcohol measures by study site
Amount of ethanol used daily
(in gram) by drinkersa mean
(SD)
P-valueb Chronic heavy drinkinga
at least 100 g ethanol daily %
(CI)
P-valuec Binge drinkinga at least one episode
of 200 g ethanol consumption
weekly % (CI)
P-valuec
Austria 175.5 (121.1) 0.1700 76.9 (53.1–100.0) 0.0667 53.8 (25.6–82.1) 0.2312
France 139.4 (103.2) 0.9205 57.2 (51.3–63.1) 0.1643 36.9 (31.1–42.7) 0.1059
Germany 223.5 (133.7) <0.0001* 81.0 (75.8–86.1) <0.0001* 67.3 (61.1–73.4) <0.0001*
Hungary 133.3 (116.0) 0.1404 49.8 (43.2–56.4) 0.0880 47.5 (40.9–54.1) 0.0914
Italy 149.7 (110.6) 0.2710 57.7 (50.4–65.1) 0.2662 34.9 (27.8–41.9) 0.0614
Latvia 96.9 (97.9) <0.0001* 36.6 (29.6–43.5) <0.0001* 37.1 (30.1–44.1) 0.0759
Poland 91.0 (83.2) <0.0001* 33.6 (27.5–39.8) <0.0001* 25.2 (19.5–30.9) <0.0001*
Spain 148.5 (107.9) 0.4141 57.0 (49.1–65.0) 0.4034 42.3 (34.3–50.2) 0.9044
Total 141.1 (116.0) 53.7 (51.2–56.3) 41.9 (39.3–44.4)
SD = standard deviation. CI = 95% CI based on standard error.
aAnalyses were computed on patients reporting alcohol use of at least 10 g ethanol daily during the past 12 months, excluding 285 patients.
bANOVA run on amount of alcohol used daily, using study site, age and sex as factors. Overall model was signiﬁcant and was followed by ANOVAs comparing
overall mean with mean of each study site, including age and sex as further factors.
cLogistic regression run on proportion of patients reporting chronic heavy drinking/binge drinking, using study site (dummy coded), age and sex as predictors.
Overall models were signiﬁcant and were followed by logistic regressions using single study site dummy variables and sex and age as predictors (P-values presented).
*Signiﬁcant Bonferroni-adjusted P-value < 0.01/9 (number of ANOVAs/logistic regressions): <0.0011.
Table 4. Current DSM-IVAUD criteria experienced by sex
Male (N =1,277) Female (N = 488) All (N = 1,767)
At least one DSM-IVAUD criterion % (CI) 90.8 (89.2–92.4) 90.1 (87.5–92.8) 90.6 (89.3–92.0)
At least two DSM-IVAUD criteria % (CI) 84.1 (82.1–86.1) 82.5 (79.1–85.9) 83.7 (81.9–85.4)
Mean number of DSM-IVAUD criteria (range: 0–11) (SD) 5.5 (3.3) 5.2 (3.2) 5.4 (3.3)
DSM-IVAD % (CI)
Need for markedly increased amounts of alcohol to achieve intoxication
or desired effect; or markedly diminished effect with continued use of
the same amount of alcohol
67.3 (64.7–69.8) 67.4 (63.2–71.5) 67.3 (65.1–69.5)
The characteristic withdrawal syndrome for alcohol; or drinking (or using
a closely related substance) to relieve or avoid withdrawal symptoms
54.7 (52.0–57.4) 52.5 (48.0–56.9) 54.1 (51.8–56.5)
Drinking in larger amounts or over a longer period than intended 61.4 (58.7–64.1) 59.1 (54.7–63.5) 60.8 (58.5–63.1)
Persistent desire or one or more unsuccessful efforts to cut down or
control drinking
59.3 (56.6–62.0) 59.7 (55.3–64.1) 59.4 (57.1–61.7)
Important social, occupational or recreational activities given up or
reduced because of drinking
38.9 (36.3–41.6) 36.4 (32.1–40.7) 38.3 (36.0–40.6)
A great deal of time spent in activities necessary to obtain alcohol, to use it
or to recover from the effects of drinking
41.5 (38.8–44.2) 41.5 (37.1–45.9) 41.6 (39.3–43.9)
Continued drinking despite knowledge of having a persistent or recurrent
physical or psychological problem that is likely to be caused or
exacerbated by drinking
42.5 (39.7–45.2) 41.9 (37.5–46.3) 42.3 (40.0–44.6)
Mean number of DSM-IVAD symptoms (range: 0–7) (SD) 3.7 (2.3) 3.6 (2.4) 3.6 (2.4)
DSM-IV alcohol abuse % (CI)
Recurrent use of alcohol resulting in a failure to fulﬁll major role
obligations at work, school or home
75.5 (73.1–77.8) 73.2 (69.2–77.1) 74.9 (72.8–76.9)
Recurrent alcohol use in situations in which it is physically hazardous 45.7 (42.9–48.4) 33.6 (29.4–37.8) 42.4 (40.1–44.7)
Recurrent alcohol-related legal problems 23.3 (20.9–25.6) 14.2 (11.1–17.3) 20.8 (18.9–22.7)
Continued alcohol use despite having persistent or recurrent social or
interpersonal problems caused or exacerbated by the effects of alcohol
43.8 (41.1–46.6) 42.1 (37.7–46.5) 43.4 (41.1–45.7)
Mean number of DSM-IV alcohol abuse symptoms (range: 0–4) (SD) 1.9 (1.3) 1.6 (1.2) 1.8 (1.3)
DSM-IV = Diagnostic and Statistic Manual of Mental Disorders, 4th edition. AUD =Alcohol use disorder, comprised of AD or alcohol abuse diagnoses. CI = 95%
CI based on standard error. SD = standard deviation.
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Limitations
Before we discuss the implications of our ﬁndings, we would like to
point out limitations: while this study is to our knowledge the largest
representative study on patients in AUD treatment in different Euro-
pean countries, the sampling was driven by the local systems, and
the resulting samples had some degree of heterogeneity. Part of this re-
ﬂects the reality of varying treatment systems and guidelines in Europe
(Rehm et al., 2013b), another part may also reﬂect decisions of the
country’s principal investigators in our study. To achieve statistical
representativeness for the entire EU in the sense of a roster of all SC
facilities and a probability sampling scheme across all possible facil-
ities was not possible, as such a roster does not exist; and partly
seems to be impossible due to different deﬁnitions of what constitutes
specialized treatment in various countries. Nevertheless, we achieved
regionally and for France, Hungary and Latvia even nationally repre-
sentative samples with sufﬁcient response rates of the most common
treatment options available to people with AUDs in the selected
regions.
The interpretation of associations presented above cannot be in-
terpreted as to reﬂect causality, as we base all our conclusions on
cross-sectional data. Furthermore, some of our comparisons are suf-
fering from a general scarcity of natural history studies of AUDs
[such as (Vaillant, 1995)], indicating that more research is needed
in this area.
CONCLUSION
The present publication ﬁlls a gap in the literature giving characteris-
tics about typical treatment populations in various European coun-
tries. While treatment systems vary considerably, one characteristic
was consistent across all countries and regions: patients in European
specialized care settings for AUDs had high average alcohol consump-
tion and extended binges before entering treatment, and showed a
high degree of comorbidity. As shown above, the levels of alcohol con-
sumption and comorbidity in our samplewere higher than the levels in
samples of people with untreated AUDs (Rehm et al., 2015a). In
other words, treatment seems to be sought by patients and/or indi-
cated by professionals only when problems with consumption and as-
sociated comorbidity move beyond a high threshold. This observation
is consistent with the overall low treatment rate for AUD (Alonso
et al., 2004; Rehm et al., 2013c). How could this rate be increased?
Family physicians as the entry point to the health care system in
many countries are a pivotal cornerstone to earlier detection of alco-
hol problems followed by brief intervention or referral to specialized
care (Babor et al., 2001, 2007). Even though there is evidence that
early detection and brief interventions is effective in reducing drinking
(Kaner et al., 2007) and alcohol-attributable harm (Rehm and
Roerecke, 2013; Rehm et al., 2013c), implementation of screening
for AUD in primary care has been slow in Europe. Catalonia seems
to be leading the way here, with almost 1,500,000 people screened
for problem use in 2012 (Generalitat de Catalunia, 2013), but studies
on impact of these public health measures are still lacking. Overall,
given the high comorbidity and disability shown here, health care sys-
tems in the EU should ﬁnd a way to detect cases of AUD earlier and
include them into the treatment system.
SUPPLEMENTARY MATERIAL
Supplementary material is available at Alcohol and Alcoholism
online.
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